COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

1. (Canceled)

2. (Canceled)

3. (Currently amended) A compound according to ~~claim 2, wherein~~ formula (I):

$(R^2,R^3)A^3$-A^4-A^5-A^6-A^7-A^8-A^9-A^{10}-A^{11}-A^{12}-A^{13}-A^{14}-A^{15}-A^{16}-A^{17}-A^{18}-A^{19}-A^{20}-A^{21}-A^{22}-A^{23}-A^{24}-A^{25}-A^{26}-A^{27}-A^{28}- A^{29}-A^{30}-A^{31}-A^{32}-A^{33}-A^{34}-A^{35}-A^{36}-R^1

(I)

wherein:

A^3 is Ile, Leu, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, or Aib, or is deleted;

A^4 is Lys, Arg, hArg, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^5 is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^6 is Glu, Asp, Gln, Asn, Lys, Arg, Orn, Dab, Dap, hArg, or Acc, or is deleted;

A^7 is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A^8 is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^9 is Gly, Ala, Aib, or Acc, or is deleted;

A^{10} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{11} is Asp, Glu, Gln, Asn, or Acc, or is deleted;

A^{12} is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, or Acc, or is deleted;

A^{13} is Ser, Thr, Aib, Act, Ala, Acc, Abu, or Val, or is deleted;

A^{14} is Pro, Thz, Dmt, Dhp, Ktp, 4Hyp, 3Hyp, Pip, Tic, Oic, or Inc, or is deleted;

A^{15} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{16} is Glu, Asp, Gln, Asn, or Acc, or is deleted;

A^{17} is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe, or is deleted;

A^{18} is Asn, Gln, Glu, Asp, Aib, or Acc, or is deleted;

A^{19} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, Acc, or HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or is deleted;

A^{20} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic, or is deleted;

A^{21} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic, or is deleted;

A^{22} is Ala, Aib, Gly, Abu, Val, Nva, Apc, Act, Acc, or N-Me-Ala, or is deleted;

A^{23} is Ser, Thr, Aib, Act, Ala, Acc, Abu, Val, or DTrp, or is deleted;

A^{24} is Leu, Ile, Nle, Tle, hLeu, Cha, Val, Ala, Nva, Abu, Acc, Aib, Trp, or Phe, or is deleted;

A^{25} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, 2Fua, Apc, Aib, Acc, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or (X^1,X^2,X^3,X^4,X^5-)Phe, or is deleted;

A^{27} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, or Aic;

A^{28} is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A^{29} is Asn, Gln, Glu, Asp, Acc, Trp, or Aib;

A^{30} is Leu, Ile, Nle, Tle, hLeu, Trp, Cha, Val, Ala, Nva, Abu, Acc, Aib, or Phe;

A^{31} is Val, Leu, Ile, Nle, Tle, hLeu, Cha, Ala, Nva, Abu, Acc, Aib, Trp, or Phe;

A^{32} is Thr, Ser, Aib, Act, Ala, Acc, Abu, Trp, DTrp, or Val;

A^{33} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc;

A^{34} is Gln, Asn, Glu, Asp, Acc, Aib, or Apc;

A^{35} is Arg, hArg, Lys, Orn, Dab, Dap, Apc, Aib, HN-CH($(CH_2)_n$-N(R^4R^5))-C(O), or Acc; ~~and~~

A^{36} is Tyr, Phe, hPhe, 2Thi, 3Thi, Taz, 2Fua, Trp, 2Nal, 1Nal, Cha, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, Acc, Aic, or Apc;

R^1 is OH or NH_2, (C_1-C_{30})alkoxy, or NH-X^6-CH_2-Z^0, wherein X^6 is a (C_1-C_{12})hydrocarbon moiety, and Z^0 is -H, -OH, -CO_2H or -C(O)NH_2;

R^2 and R^3 each is, independently for each occurrence, selected from the group consisting of -H, (C_1-C_{30})alkyl, (C_1-C_{30})heteroalkyl, (C_1-C_{30})acyl, (C_2-C_{30})alkenyl, (C_2-C_{30})alkynyl, aryl(C_1-C_{30})alkyl, aryl(C_1-C_{30})acyl, substituted (C_1-C_{30})alkyl, substituted (C_1-C_{30})heteroalkyl, substituted (C_2-C_{30})acyl, substituted (C_2-C_{30})alkenyl, substituted (C_2-C_{30})alkynyl, substituted aryl(C_1-C_{30})alkyl, and substituted aryl(C_1-C_{30})acyl,

provided that when R^2 is (C_1-C_{30})acyl, aryl(C_1-C_{30})acyl, substituted (C_2-C_{30})acyl, or substituted aryl(C_1-C_{30})acyl, R^3 is -H, (C_1-C_{30})alkyl, (C_1-C_{30})heteroalkyl, (C_2-C_{30})alkenyl, (C_2-C_{30})alkynyl, aryl(C_1-C_{30})alkyl, substituted (C_1-C_{30})alkyl, substituted (C_1-C_{30})heteroalkyl, substituted (C_2-C_{30})alkenyl, substituted (C_2-C_{30})alkynyl, or substituted aryl(C_1-C_{30})alkyl;

R^4 and R^5 each is, independently for each occurrence, selected from the group consisting of -H, (C_1-C_{40})alkyl, (C_2-C_{40})acyl, (C_1-C_{30})alkylsulfonyl, and -C(NH)NH_2,

provided that when R^4 is (C_1-C_{40})acyl, (C_1-C_{30})alkylsulfonyl, or -C(NH)NH_2, then R^5 is -H or (C_1-C_{40})alkyl;

n is, independently for each occurrence, 1, 2, 3, 4 or 5; and

X^1, X^2, X^3, X^4, and X^5 each is, independently for each occurrence, selected from the group consisting of -H, -F, -Cl, -Br, -I, (C_1-C_{10})alkyl, substituted (C_1-C_{10})alkyl, aryl, substituted aryl, -OH, -NH_2, -NO_2, and -CN;

provided that:

(a) said peptide comprises at least one amino acid selected from the group consisting of:

(i) Acc at A^3, A^6, A^7, A^9, A^{10}, A^{11}, A^{12}, A^{15}, A^{16}, A^{17}, A^{18}, A^{20}, A^{21}, A^{22}, A^{24}, A^{27}, A^{28}, A^{29}, A^{30}, A^{31}, A^{32}, or A^{34};

(ii) Act at A^3, A^7, A^{12}, A^{13}, A^{22}, A^{23}, or A^{32};

(iii) Apc at A^4, A^7, A^{12}, A^{19}, A^{22}, A^{25}, A^{26}, A^{33}, A^{34}, A^{35}, or A^{36};

(iv) Aib at A^6, A^7, A^9, A^{10}, A^{11}, A^{12}, A^{13}, A^{15}, A^{16}; A^{18}, A^{22}, A^{29}, or A^{32};

(v) Thz, Dmt, Dhp, Ktp, or Tic at A^5, A^8, or A^{14};

(vi) (3,4,5-F)Phe or (2,3,4,5,6-F)Phe at A^{20}, A^{21}, A^{26}, A^{27}, or A^{36};

(vii) 2Fua at A^{20}, A^{21}, A^{26}, or A^{27};

(viii) Taz at A^{20}, A^{21}, or A^{26}; and

(ix) 2Pal, 3Pal, 4Pal, 2Thi or 3Thi at A^{26};

(b) if A^3 - A^{21} are deleted and (i) A^{22} is Aib or (ii) A^{36} is (3,4,5-F)Phe or (2,3,4,5,6-F)Phe, then A^{27} is not 2Thi, Trp, 2Nal, or (X^1,X^2,X^3,X^4,X^5)Phe, wherein X^1 is *p*-chloro and X^2, X^3, X^4 and X^5 each is -H; and

(c) each amino acid A^m of formula (I) may be deleted only if A^{m-1} is deleted, wherein m is an integer ranging in value from 4 - 26, inclusive;

or a pharmaceutically acceptable salt thereof.

4. (Original) A compound according to claim 3, wherein:

A^3 is Ile, Leu, Nle, Val, Acc, or Aib, or is deleted;

A^4 is Lys, Arg, hArg, Orn, or Apc, or is deleted;

A^5 is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^6 is Glu, Asp, Gln, or Acc, or is deleted;

A^7 is Ala, Aib, Abu, Act, or Acc, or is deleted;

A^8 is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^9 is Gly, Aib, or Acc, or is deleted;

A^{10} is Glu, Asp, Gln, or Acc or is deleted;

A^{11} is Asp, Glu, Asn, or Acc or is deleted;

A^{12} is Ala, Aib, Act, or Acc, or is deleted;

A^{13} is Ser, Thr, Aib, Act, or Acc, or is deleted;

A^{14} is Pro, Thz, Dmt, 4Hyp, or 3Hyp, or is deleted;

A^{15} is Glu, Asp, Gln, or Acc, or is deleted;

A^{16} is Glu, Asp, Gln, or Acc or is deleted;

A^{17} is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;

A^{18} is Asn, Gln, Asp, Aib, or Acc or is deleted;

A^{19} is Arg, hArg, Lys, or Apc, or is deleted;

A^{20} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{21} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{22} is Ala, Aib, Abu, or Acc, or is deleted;

A^{23} is Ser, Thr, Aib, Act, or Ala, or is deleted;

A^{24} is Leu, Ile, Nle, Val, Acc, or Aib, or is deleted;

A^{25} is Arg, hArg, Lys, or Apc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, Apc, or $(X^1,X^2,X^3,X^4,X^5$-)Phe, or is deleted;

A^{27} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe or Acc;

A^{28} is Leu, Ile, Nle, Val, Acc or Aib;

A^{29} is Asn, Gln, Asp, Acc or Aib;

A^{30} is Leu, Ile, Nle, Val, Acc or Aib;

A^{31} is Val, Leu, Ile, Ala, Acc or Aib;

A^{32} is Thr, Ser, Aib, Act or Acc;

A^{33} is Arg, hArg, Lys or Apc;

A^{34} is Gln, Asn, Glu, Aib or Apc;

A^{35} is Arg, hArg, Lys or Apc; and

A^{36} is Tyr, Phe, 2Pal, 3Pal, 4Pal, (X^1,X^2,X^3,X^4,X^5)Phe or Apc;

or a pharmaceutically acceptable salt thereof.

5. (Original) A compound according to claim 4, wherein:

A^3 is Ile or Acc, or is deleted;

A^4 is Lys or Apc, or is deleted;

A^5 is Pro or is deleted;

A^6 is Glu or Acc, or is deleted;

A^7 is Ala, Act, or Acc, or is deleted;

A^8 is Pro or is deleted;

A^9 is Gly or Acc, or is deleted;

A^{10} is Glu or Acc, or is deleted;

A^{11} is Asp or Acc, or is deleted;

A^{12} is Ala, Act, or Acc, or is deleted;

A^{13} is Ser, Act, or Acc, or is deleted;

A^{14} is Pro or is deleted;

A^{15} is Glu or Acc, or is deleted;

A^{16} is Glu or Acc, or is deleted;

A^{17} is Leu or Acc, or is deleted;

A^{18} is Asn or Acc, or is deleted;

A^{19} is Arg or Apc, or is deleted;

A^{20} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{21} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc, or is deleted;

A^{22} is Ala, Aib, or Acc, or is deleted;

A^{23} is Ser or Act, or is deleted;

A^{24} is Leu or Acc, or is deleted;

A^{25} is Arg or Apc, or is deleted;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, Taz, Apc, or $(X^1,X^2,X^3,X^4,X^5$-)Phe, or is deleted;

A^{27} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Acc;

A^{28} is Leu, or Acc;

A^{29} is Asn or Acc;

A^{30} is Leu or Acc;

A^{31} is Val, Leu or Acc;

A^{32} is Thr, Act, or Acc;

A^{33} is Arg or Apc;

A^{34} is Gln or Apc;

A^{35} is Arg or Apc; and

A^{36} is Tyr, (X^1,X^2,X^3,X^4,X^5)Phe, or Apc;

or a pharmaceutically acceptable salt thereof.

6. (Original) A compound according to claim 5, wherein:

Acc is, independently for each occurrence, A5c or A6c; and

(X^1,X^2,X^3,X^4,X^5)Phe is, independently for each occurrence, (3,4,5-F)Phe or (2,3,4,5,6-F)Phe; or a pharmaceutically acceptable salt thereof.

7. (Original) A compound according to claim 6, wherein:

A^3 is Ile or is deleted;

A^4 is Lys or is deleted;

A^6 is Glu or is deleted;

A^7 is Ala or is deleted;

A^9 is Gly or is deleted;

A^{10} is Glu or is deleted;

A^{11} is Asp or is deleted;

A^{12} is Ala or is deleted;

A^{13} is Ser or is deleted;

A^{14} is Pro or is deleted;

A^{15} is Glu or is deleted;

A^{16} is Glu or is deleted;

A^{17} is Leu or is deleted;

A^{18} is Asn or is deleted;

A^{19} is Arg or is deleted;

A^{20} is Tyr or is deleted;

A^{21} is Tyr or is deleted;

A^{22} is Ala, Aib, or A5c, or is deleted;

A^{23} is Ser or is deleted;

A^{24} is Leu or A6c;

A^{25} is Arg;

A^{26} is His, 2Pal, D2Pal, 3Pal, 4Pal, or Taz;

A^{27} is Tyr or (3,4,5-F)Phe;

A^{28} is Leu, or A6c;

A^{29} is Asn;

A^{30} is Leu or A6c;

A^{31} is Val, Leu, A5c or A6c;

A^{32} is Thr;

A^{33} is Arg;

A^{34} is Gln; and

A^{36} is Tyr;

or a pharmaceutically acceptable salt thereof.

8. (Original) A compound according to claim 6, wherein said compound is according to the formula:

((2,3,4,5,6-F)Phe^{20})hPYY(3-36)NH_2;	(SEQ ID NO. 31)
((2,3,4,5,6-F)Phe^{21})hPYY(3-36)NH_2;	(SEQ ID NO. 32)
Ac-((2,3,4,5,6-F)Phe^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 33)
Ac-((2,3,4,5,6-F)Phe^{26})hPYY(24-36)NH_2;	(SEQ ID NO. 34)
((2,3,4,5,6-F)Phe^{26})hPYY(3-36)NH_2;	(SEQ ID NO. 35)
Ac-((2,3,4,5,6-F)Phe^{27})hPYY(22-36)NH_2;	(SEQ ID NO. 36)
Ac-((2,3,4,5,6-F)Phe^{27})hPYY(24-36)NH_2;	(SEQ ID NO. 37)
((2,3,4,5,6-F)Phe^{27})hPYY(3-36)NH_2;	(SEQ ID NO. 38)
Ac-((2,3,4,5,6-F)Phe^{36})hPYY(22-36)NH_2;	(SEQ ID NO. 39)
Ac-((2,3,4,5,6-F)Phe^{36})hPYY(24-36)NH_2;	(SEQ ID NO. 40)
((2,3,4,5,6-F)Phe^{36})hPYY(3-36)NH_2;	(SEQ ID NO. 41)
((3,4,5-F)Phe^{20})hPYY(3-36)NH_2;	(SEQ ID NO. 42)
((3,4,5-F)Phe^{21})hPYY(3-36)NH_2;	(SEQ ID NO. 43)
Ac-((3,4,5-F)Phe^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 44)
Ac-((3,4,5-F)Phe^{26})hPYY(24-36)NH_2;	(SEQ ID NO. 45)
((3,4,5-F)Phe^{26})hPYY(3-36)NH_2;	(SEQ ID NO. 46)
Ac- ((3,4,5-F)Phe^{27})hPYY(22-36)NH_2;	(SEQ ID NO. 15)
Ac-((3,4,5-F)Phe^{27})hPYY(24-36)NH_2;	(SEQ ID NO. 47)
((3,4,5-F)Phe^{27})hPYY(3-36)NH_2;	(SEQ ID NO. 12)
Ac-((3,4,5-F)Phe^{36})hPYY(22-36)NH_2;	(SEQ ID NO. 48)
Ac-((3,4,5-F)Phe^{36})hPYY(24-36)NH_2;	(SEQ ID NO. 49)
((3,4,5-F)Phe^{36})hPYY(3-36)NH_2;	(SEQ ID NO. 50)
Ac-(D2Pal^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 26)
Ac-(2Pal^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 27)
Ac-(2Pal^{26}, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 18)
Ac-(3Pal^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 14)
(3Pal^{26})hPYY(3-36)NH_2;	(SEQ ID NO. 5)
Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2;	(SEQ ID NO. 16)

Ac-(4Pal^{26})hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

Ac-(A5c^{22})hPYY(22-36)NH_2 (SEQ ID NO. 4)

Ac-(A5c^{31})hPYY(22-36)NH_2; (SEQ ID NO. 24)

Ac-(A5c^{31})hPYY(24-36)NH_2; (SEQ ID NO. 51)

(A5c^{31})hPYY(3-36)NH_2 (SEQ ID NO. 3)

(A6c^{10})hPYY(3-36)NH_2; (SEQ ID NO. 52)

(A6c^{11})hPYY(3-36)NH_2; (SEQ ID NO. 53)

(A6c^{12})hPYY(3-36)NH_2; (SEQ ID NO. 54)

(A6c^{13})hPYY(3-36)NH_2; (SEQ ID NO. 55)

(A6c^{15})hPYY(3-36)NH_2; (SEQ ID NO. 56)

(A6c^{16})hPYY(3-36)NH_2; (SEQ ID NO. 57)

(A6c^{17})hPYY(3-36)NH_2; (SEQ ID NO. 58)

(A6c^{18})hPYY(3-36)NH_2; (SEQ ID NO. 59)

(A6c^{20})hPYY(3-36)NH_2; (SEQ ID NO. 60)

(A6c^{21})hPYY(3-36)NH_2; (SEQ ID NO. 61)

Ac-(A6c^{22})hPYY(22-36)NH_2; (SEQ ID NO. 62)

(A6c^{22})hPYY(3-36)NH_2; (SEQ ID NO. 63)

Ac-(A6c^{24})hPYY(22-36)NH_2; (SEQ ID NO. 25)

Ac-(A6c^{24})hPYY(24-36)NH_2; (SEQ ID NO. 64)

(A6C^{24})hPYY(3-36)NH_2; (SEQ ID NO. 10)

Ac-(A6c^{24}, Leu^{31})hPYY(24-36)NH_2; (SEQ ID NO. 28)

Ac-(A6c^{27})hPYY(22-36)NH_2; (SEQ ID NO. 65)

Ac-(A6c^{27})hPYY(24-36)NH_2; (SEQ ID NO. 66)

(A6c^{27})hPYY(3-36)NH_2; (SEQ ID NO. 67)

Ac-(A6c^{28})hPYY(22-36)NH_2; (SEQ ID NO. 23)

Ac-(A6c^{28})hPYY(24-36)NH_2; (SEQ ID NO. 68)

(A6c^{28})hPYY(3-36)NH_2; (SEQ ID NO. 8)

Ac-(A6c^{28}, Leu^{31})hPYY(24-36)NH_2; (SEQ ID NO. 29)

Ac-(A6c^{29})hPYY(22-36)NH_2; (SEQ ID NO. 69)

Ac-(A6c^{29})hPYY(24-36)NH_2; (SEQ ID NO. 70)

(A6c^{29})hPYY(3-36)NH_2; (SEQ ID NO. 71)

(A6c^{3})hPYY(3-36)NH_2; (SEQ ID NO. 72)

Ac-(A6c^{30})hPYY(22-36)NH_2; (SEQ ID NO. 22)

Ac-(A6c^{30})hPYY(24-36)NH_2;	(SEQ ID NO. 73)
(A6c^{30})hPYY(3-36)NH_2;	(SEQ ID NO. 9)
Ac-(A6c^{31})hPYY(22-36)NH_2;	(SEQ ID NO. 21)
Ac-(A6c^{31})hPYY(24-36)NH_2;	(SEQ ID NO. 30)
(A6c^{31})hPYY(3-36)NH_2;	(SEQ ID NO. 74)
Ac-(A6c^{32})hPYY(22-36)NH_2;	(SEQ ID NO. 75)
Ac-(A6c^{32})hPYY(24-36)NH_2;	(SEQ ID NO. 76)
(A6c^{32})hPYY(3-36)NH_2;	(SEQ ID NO. 77)
(A6c^{6})hPYY(3-36)NH_2;	(SEQ ID NO. 78)
(A6c^{7})hPYY(3-36)NH_2;	(SEQ ID NO. 79)
(A6c^{9})hPYY(3-36)NH_2;	(SEQ ID NO. 80)
(Act^{12})hPYY(3-36)NH_2;	(SEQ ID NO. 81)
(Act^{13})hPYY(3-36)NH_2;	(SEQ ID NO. 82)
Ac-(Act^{23})hPYY(22-36)NH_2;	(SEQ ID NO. 83)
(Act^{23})hPYY(3-36)NH_2;	(SEQ ID NO. 84)
Ac-(Act^{32})hPYY(22-36)NH_2;	(SEQ ID NO. 85)
Ac-(Act^{32})hPYY(24-36)NH_2;	(SEQ ID NO. 86)
(Act^{32})hPYY(3-36)NH_2;	(SEQ ID NO. 87)
(Act^{7})hPYY(3-36)NH_2;	(SEQ ID NO. 88)
Ac-(Aib^{22})hPYY(22-36)NH_2;	(SEQ ID NO. 89)
(Aib^{22})hPYY(3-36)NH_2;	(SEQ ID NO. 11)
(Apc^{19})hPYY(3-36)NH_2;	(SEQ ID NO. 90)
Ac-(Apc^{25})hPYY(22-36)NH_2;	(SEQ ID NO. 91)
Ac-(Apc^{25})hPYY(24-36)NH_2;	(SEQ ID NO. 92)
(Apc^{25})hPYY(3-36)NH_2;	(SEQ ID NO. 93)
Ac-(Apc^{26})hPYY(22-36)NH_2;	(SEQ ID NO. 94)
Ac-(Apc^{26})hPYY(24-36)NH_2;	(SEQ ID NO. 95)
(Apc^{26})hPYY(3-36)NH_2;	(SEQ ID NO. 96)
Ac-(Apc^{33})hPYY(22-36)NH_2;	(SEQ ID NO. 97)
Ac-(Apc^{33})hPYY(24-36)NH_2;	(SEQ ID NO. 98)
(Apc^{33})hPYY(3-36)NH_2;	(SEQ ID NO. 99)
Ac-(Apc^{34})hPYY(22-36)NH_2;	(SEQ ID NO. 100)
Ac-(Apc^{34})hPYY(24-36)NH_2;	(SEQ ID NO. 101)
(Apc^{34})hPYY(3-36)NH_2;	(SEQ ID NO. 102)

Ac-(Apc^{35})hPYY(22-36)NH_2; (SEQ ID NO. 103)

Ac-(Apc^{35})hPYY(24-36)NH_2; (SEQ ID NO. 104)

(Apc^{35})hPYY(3-36)NH_2; (SEQ ID NO. 7)

Ac-(Apc^{36})hPYY(22-36)NH_2; (SEQ ID NO. 105)

Ac-(Apc^{36})hPYY(24-36)NH_2; (SEQ ID NO. 106)

(Apc^{36})hPYY(3-36)NH_2; (SEQ ID NO. 107)

(Apc^{4})hPYY(3-36)NH_2; (SEQ ID NO. 108)

(Taz^{26})hPYY(3-36)NH_2; (SEQ ID NO. 6)

Ac-(Taz^{26})hPYY(22-36)NH_2; (SEQ ID NO. 20)

Ac-(Taz^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 19)

or a pharmaceutically acceptable salt thereof.

9. (Previously presented) A compound according to claim 8, wherein said compound is according to the formula:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)

Ac-[A5C^{22}]hPYY(22-36)NH_2 (SEQ ID NO. 4)

[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)

[Taz^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 6)

[Apc^{35}]hPYY(3-36)NH_2; (SEQ ID NO. 7)

[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)

[A6C^{30}]hPYY(3-36)NH_2; (SEQ ID NO. 9)

[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)

[Aib^{22}]hPYY(3-36)NH_2; (SEQ ID NO. 11)

[((3,4,5-F)Phe)^{27}]hPYY(3-36)NH_2; (SEQ ID NO. 12)

Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-[3Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 14)

Ac-[((3,4,5-F)Phe)^{27}]hPYY(22-36)NH_2; (SEQ ID NO. 15)

Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

Ac-(2Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 18)

Ac-(Taz^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 19)

Ac-[Taz^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 20)

Ac-[A6c^{31}]hPYY(22-36)NH_2; (SEQ ID NO. 21)

Ac-[A6c^{30}]hPYY(22-36)NH_2; (SEQ ID NO. 22)

Ac-[A6c^{28}]hPYY(22-36)NH_2; (SEQ ID NO. 23)
Ac-[A5c^{31}]hPYY(22-36)NH_2; (SEQ ID NO. 24)
Ac-[A6C^{24}]hPYY(22-36)NH_2; (SEQ ID NO. 25)
Ac-[D2Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 26)
Ac-[2Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 27)
Ac-[A6C^{24}, Leu^{31}]hPYY(24-36)NH_2; (SEQ ID NO. 28)
Ac-[A6C^{28}, Leu^{31}]hPYY(24-36)NH_2; (SEQ ID NO. 29)
Ac-[A6C^{31}]hPYY(24-36)NH_2; (SEQ ID NO. 30)
Ac-(A6c^{24})hPYY(24-36)NH_2; (SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

10. (Original) A compound according to claim 9, wherein said compound is:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)
[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)
[Taz^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 6)
[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)
[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)
[Aib^{22}]hPYY(3-36)NH_2; (SEQ ID NO. 11)
[((3,4,5-F)Phe)^{27}]hPYY(3-36)NH_2; (SEQ ID NO. 12)
Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)
Ac-[3Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 14)
Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)
Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

11. (Original) A compound according to claim 9, wherein said compound is:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)
[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)
[Taz^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 6)
[Apc^{35}]hPYY(3-36)NH_2; (SEQ ID NO. 7)
[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)
[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)
[Aib^{22}]hPYY(3-36)NH_2; (SEQ ID NO. 11)
Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-[3Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 14)

Ac-(3Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 16)

Ac-(4Pal^{26}, Leu^{31})hPPY(24-36)NH_2; (SEQ ID NO. 17)

or a pharmaceutically acceptable salt thereof.

12. (Previously presented) A compound according to claim 9, wherein said compound is:

[A5C^{31}]hPYY(3-36)NH_2 (SEQ ID NO. 3)

[3Pal^{26}]hPYY(3-36)NH_2; (SEQ ID NO. 5)

[A6C^{28}]hPYY(3-36)NH_2; (SEQ ID NO. 8)

[A6C^{24}]hPYY(3-36)NH_2; (SEQ ID NO. 10)

Ac-[4Pal^{26}]hPYY(22-36)NH_2; (SEQ ID NO. 13)

Ac-(A6c^{24})hPYY(24-36)NH_2; (SEQ ID NO. 64)

or a pharmaceutically acceptable salt thereof.

13. (Currently amended) A pharmaceutical composition comprising a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

14. (Withdrawn—currently amended) A method of decreasing excess intestinal water and electrolyte secretion in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

15. (Withdrawn—currently amended) A method of regulating cell proliferation in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

16. (Withdrawn) A method of claim 15, wherein said cell is a gastrointestinal cell.

17. (Withdrawn) A method of claim 15, wherein said cell is an epithelial cell.

18. (Withdrawn—currently amended) A method of augmenting nutrient transport in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

19. (Withdrawn—currently amended) A method of regulating lipolysis in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

20. (Withdrawn—currently amended) A method of regulating blood flow in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

21. (Withdrawn—currently amended) A method of facilitating weight loss, appetite decrease, weight maintenance, treating obesity, treating diabetes, treating complications of diabetes including retinopathy, or treating cardiovascular disorders in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof.

22. (Withdrawn) A method according to claim 21, wherein excessive weight is a contributing factor to a disease or condition including hypertension, diabetes, dyslipidemia, cardiovascular disease, gall stones, osteoarthritis and cancers.

23. (Withdrawn) A method according to claim 22, wherein said facilitation of weight loss reduces the likelihood of such diseases or conditions or where said facilitation of weight loss comprises at least part of a treatment for such diseases or conditions.

24. (Withdrawn—currently amended) A method of antagonizing the effects of PYY(3-36) in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a compound according to ~~claim 1~~ claim 3, or a pharmaceutically acceptable salt thereof, wherein said compound is a PYY antagonist.

25. (Withdrawn) A method according to claim 24, wherein said antagonist effects in said mammal comprise facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase.

26. (Withdrawn) A method according to claim 25, wherein said facilitating weight gain, facilitating maintenance in weight, and/or facilitating appetite increase is indicated in a mammal having a disease or disorder, or under going a treatment, accompanied by weight loss.

27. (Withdrawn) A method according to claim 26, wherein said diseases or disorders accompanied by weight loss include anorexia, bulimia, cancer cachexia, AIDS, wasting, cachexia, and wasting in frail elderly.

28. (Withdrawn) A method according to claim 26, wherein said treatment accompanied by weight loss comprises chemotherapy, radiation therapy, temporary or permanent immobilization, or dialysis.